This document discusses NGAL, a protein biomarker for acute kidney injury (AKI) that is measured by BioPorto's NGAL test. It notes that AKI affects millions annually and leads to many deaths. The NGAL test provides a fast, inexpensive way to detect AKI within 2 hours and guide treatment. BioPorto has patents on the NGAL cutoff value and a 1-step homogeneous test. It is finalizing distribution agreements with major diagnostic companies. The global market for NGAL tests is estimated at 200-300 million tests per year by 2021, which could earn BioPorto over 500 million euros annually. However, challenges remain regarding patent issues and funding.